News for Healthier Living
New Therapeutic Target Expands Options for Multiple Myeloma
In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma.
July 22, 2026
August 1 2026July 31 2026July 30 2026July 29 2026July 28 2026July 27 2026July 26 2026July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026
|
|
|
|
|